JMJD1C and esophageal squamous cell carcinoma: circCNOT6L promotes paclitaxel resistance in ESCC by regulating the miR-194-5p/jumonji domain containing 1C (JMJD1C) axis, suggesting that circCNOT6L may be a therapeutic target for ESCC chemotherapy.